Molecular Historical Financial Ratios
| MOLN Stock | USD 5.62 0.33 6.24% |
Molecular Partners is lately reporting on over 89 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 245 will help investors to properly organize and evaluate Molecular Partners financial condition quickly.
Molecular |
About Molecular Financial Ratios Analysis
Molecular PartnersFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Molecular Partners investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Molecular financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Molecular Partners history.
Molecular Partners Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Molecular Partners stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Molecular Partners sales, a figure that is much harder to manipulate than other Molecular Partners AG multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to Molecular Partners AG. There are two different methods for calculating Molecular Partners invested capital: operating approach and financing approach. Understanding Molecular Partners invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Return On Tangible Assets
A profitability metric that measures a company's ability to generate earnings from its tangible assets.Most ratios from Molecular Partners' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Molecular Partners current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Molecular Partners' Research And Ddevelopement To Revenue is very stable compared to the past year. As of the 26th of November 2024, Cash Per Share is likely to grow to 7.77, while PTB Ratio is likely to drop 0.61.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 1.0K | 3.27 | 159.94 | 244.78 | PTB Ratio | 5.15 | 0.85 | 0.64 | 0.61 |
Molecular Partners fundamentals Correlations
Click cells to compare fundamentals
Molecular Partners Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Molecular Partners fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 18.41 | 55.52 | 59.22 | 1.06 | 16.02 | 20.88 | |
| Ptb Ratio | 6.93 | 4.84 | 5.15 | 0.85 | 0.64 | 0.61 | |
| Days Sales Outstanding | 45.63 | 110.9 | 1.0K | 3.27 | 159.94 | 244.78 | |
| Book Value Per Share | 2.53 | 4.29 | 3.46 | 7.24 | 5.38 | 5.95 | |
| Free Cash Flow Yield | (0.008138) | (0.0591) | (0.17) | 0.59 | (0.53) | (0.5) | |
| Operating Cash Flow Per Share | (0.0555) | (1.16) | (2.93) | 3.65 | (1.8) | (1.71) | |
| Capex To Depreciation | 0.75 | 0.58 | 0.51 | 0.59 | 0.24 | 0.23 | |
| Pb Ratio | 6.93 | 4.84 | 5.15 | 0.85 | 0.64 | 0.61 | |
| Ev To Sales | 14.82 | 41.98 | 52.17 | 0.62 | 6.97 | 6.62 | |
| Free Cash Flow Per Share | (0.14) | (1.23) | (2.98) | 3.61 | (1.83) | (1.73) | |
| Roic | (0.68) | (0.54) | (0.59) | 0.5 | (0.35) | (0.36) | |
| Net Income Per Share | (1.69) | (2.51) | (2.06) | 3.63 | (1.89) | (1.8) | |
| Days Of Inventory On Hand | (53.62) | (4.08) | (1.3) | 1.3E-5 | 1.5E-5 | 1.4E-5 | |
| Payables Turnover | 21.54 | 20.03 | 11.46 | 50.9 | 116.69 | 122.53 | |
| Sales General And Administrative To Revenue | 0.65 | 1.18 | 1.81 | 0.12 | 2.7 | 2.83 | |
| Research And Ddevelopement To Revenue | 2.13 | 6.0 | 5.97 | 0.27 | 6.93 | 7.28 | |
| Capex To Revenue | 0.0914 | 0.18 | 0.14 | 0.007475 | 0.0817 | 0.0561 | |
| Cash Per Share | 4.44 | 6.95 | 4.28 | 7.67 | 5.7 | 7.77 | |
| Pocfratio | (315.53) | (17.9) | (6.07) | 1.69 | (1.91) | (2.01) | |
| Interest Coverage | (1.4K) | (215.23) | (115.73) | 192.75 | (1.2K) | (1.3K) | |
| Capex To Operating Cash Flow | (1.57) | (0.0581) | (0.0144) | 0.012 | (0.009745) | (0.0102) | |
| Pfcf Ratio | (122.88) | (16.92) | (5.99) | 1.71 | (1.88) | (1.98) | |
| Days Payables Outstanding | 16.94 | 18.23 | 31.85 | 7.17 | 3.13 | 2.97 | |
| Income Quality | 0.0328 | 0.46 | 1.43 | 1.01 | 0.95 | 1.0 | |
| Roe | (0.4) | (0.67) | (0.59) | 0.5 | (0.35) | (0.37) | |
| Ev To Operating Cash Flow | (253.99) | (13.53) | (5.35) | 0.99 | (0.83) | (0.87) | |
| Pe Ratio | (10.34) | (8.27) | (8.66) | 1.7 | (1.82) | (1.91) | |
| Return On Tangible Assets | (0.35) | (0.34) | (0.37) | 0.45 | (0.31) | (0.3) | |
| Ev To Free Cash Flow | (98.92) | (12.79) | (5.28) | 1.0 | (0.82) | (0.86) | |
| Earnings Yield | (0.0956) | (0.0967) | (0.12) | 0.59 | (0.55) | (0.52) | |
| Intangibles To Total Assets | 0.007357 | 0.00185 | 0.001911 | 0.001033 | 0.001069 | 0.001204 | |
| Net Debt To E B I T D A | 2.17 | 2.12 | 1.08 | (0.71) | 1.07 | 1.12 | |
| Current Ratio | 3.49 | 3.08 | 3.5 | 14.77 | 13.35 | 14.02 | |
| Tangible Book Value Per Share | 2.49 | 4.27 | 3.45 | 7.23 | 5.38 | 5.94 | |
| Receivables Turnover | 8.0 | 3.29 | 0.36 | 111.63 | 2.28 | 2.17 | |
| Graham Number | 9.82 | 15.56 | 12.66 | 24.32 | 15.14 | 9.17 | |
| Shareholders Equity Per Share | 2.53 | 4.29 | 3.46 | 7.24 | 5.38 | 5.95 |
Pair Trading with Molecular Partners
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Molecular Partners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will appreciate offsetting losses from the drop in the long position's value.Moving against Molecular Stock
The ability to find closely correlated positions to Molecular Partners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molecular Partners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molecular Partners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molecular Partners AG to buy it.
The correlation of Molecular Partners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molecular Partners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molecular Partners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Molecular Partners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.13) | Revenue Per Share 0.182 | Quarterly Revenue Growth (0.73) | Return On Assets (0.21) | Return On Equity (0.37) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.